Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label recNY-ESO-1 + AS15 immunotherapy in NY-ESO-1-positive metastatic cutaneous melanoma
NL-OMON41308Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant NY-ESO-1 protein and AS15 in cutaneous melanoma (CM), sponsored by GSK. Primary endpoints: Occurrence of severe toxicities and Objective clinical response in overall population. Started Apr 2011; status: active, not recruiting.
02
Drugs
recombinant NY-ESO-1 proteinAS15
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON41308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41308.